HIV molecular immunology database

 

Search CTL/CD8+ T-Cell Epitope Database

Found 5 matching records:

Displaying record number 627

HXB2 Location gp160(33-42)
gp120(33-42)
DNA(6321..6350)
gp160 Epitope Map
Author Location Env(32-41 LAI)
Epitope KLWVTVYYGV Epitope Alignment
KLWVTVYYGV epitope logo
Epitope Name Env32-41
Subtype B
Species (MHC/HLA) human(A*0201)
Immunogen vaccine
Country United States
Experimental methods Chromium-release assay
Keywords dendritic cells, enhancing activity

Vaccine Details

Vaccine type protein
Vaccine strain B clade MN
Vaccine component gp160

Notes

References

Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.


Displaying record number 58643

HXB2 Location gp160(121-129)
gp120(121-129)
DNA(6585..6611)
gp160 Epitope Map
Author Location Env(120-128 LAI)
Epitope KLTPLCVTL Epitope Alignment
KLTPLCVTL epitope logo
Epitope Name Env120-128
Subtype B
Species (MHC/HLA) human(A*0201)
Immunogen vaccine
Country United States
Experimental methods Chromium-release assay
Keywords dendritic cells, enhancing activity, novel epitope

Vaccine Details

Vaccine type protein
Vaccine strain B clade MN
Vaccine component gp160

Notes

References

Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.


Displaying record number 58646

HXB2 Location gp160(813-822)
gp41(302-311)
DNA(8661..8690)
gp160 Epitope Map
Author Location Env(814-823 LAI)
Epitope SLLNATDIAV Epitope Alignment
SLLNATDIAV epitope logo
Show epitope variants
Epitope Name Env814-823
Subtype B
Species (MHC/HLA) human(A*0201)
Immunogen vaccine
Country United States
Experimental methods Chromium-release assay
Keywords dendritic cells, enhancing activity, optimal epitope, novel epitope

Vaccine Details

Vaccine type protein
Vaccine strain B clade MN
Vaccine component gp160

Notes

References

Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.


Displaying record number 58645

HXB2 Location gp160(814-822)
gp41(303-311)
DNA(8664..8690)
gp160 Epitope Map
Author Location Env(815-823 LAI)
Epitope LLNATDIAV Epitope Alignment
LLNATDIAV epitope logo
Epitope Name Env815-823
Subtype B
Species (MHC/HLA) human(A*0201)
Immunogen vaccine
Country United States
Experimental methods Chromium-release assay
Keywords dendritic cells, enhancing activity, optimal epitope, novel epitope

Vaccine Details

Vaccine type protein
Vaccine strain B clade MN
Vaccine component gp160

Notes

References

Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.


Displaying record number 58644

HXB2 Location gp160(828-836)
gp41(317-325)
DNA(8706..8732)
gp160 Epitope Map
Author Location Env(829-837 LAI)
Epitope RVIEVLQRA Epitope Alignment
RVIEVLQRA epitope logo
Epitope Name Env829-837
Subtype B
Species (MHC/HLA) human(A*0201)
Immunogen vaccine
Country United States
Experimental methods Chromium-release assay
Keywords dendritic cells, enhancing activity

Vaccine Details

Vaccine type protein
Vaccine strain B clade MN
Vaccine component gp160

Notes

References

Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Operated by Los Alamos National Security, LLC, for the U.S. Department of Energy's National Nuclear Security Administration
Copyright © 2006-2017 LANS LLC All rights reserved | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health